Order Article Reprints

Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A, Di Bernardo F, Stefani S. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals. 2022; 15(5):606. https://doi.org/10.3390/ph15050606

Migliorisi, Giuseppe, Mirella Collura, Francesca Ficili, Tiziana Pensabene, Dafne Bongiorno, Antonina Collura, Francesca Di Bernardo, and Stefania Stefani. 2022. "Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study" Pharmaceuticals 15, no. 5: 606. https://doi.org/10.3390/ph15050606

Migliorisi, G., Collura, M., Ficili, F., Pensabene, T., Bongiorno, D., Collura, A., Di Bernardo, F., & Stefani, S. (2022). Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals, 15(5), 606. https://doi.org/10.3390/ph15050606